A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health

Journal of Psychiatry and Neuroscience

Volumn 37, Issue 1, 2012, Pages 7-16

  Beaulieu, Jean Martin ^a  

^a CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN 1; BETA ARRESTIN 2; CATECHOL METHYLTRANSFERASE; CLOZAPINE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM; MONOAMINE OXIDASE INHIBITOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEU DIFFERENTIATION FACTOR; NEUROLEPTIC AGENT; OLANZAPINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN HYDROXYLASE 2; TYROSINE 3 MONOOXYGENASE; ZIPRASIDONE;

ANXIETY; BIPOLAR DISORDER; CIRCADIAN RHYTHM; CORPUS STRIATUM; DNA POLYMORPHISM; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG EFFICACY; ENZYME REGULATION; EPIGENETICS; FRONTAL CORTEX; HAPLOINSUFFICIENCY; HIPPOCAMPUS; HUMAN; MENTAL DISEASE; MOOD; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SCHIZOPHRENIA; SEROTONIN RELEASE; SEROTONINERGIC TRANSMISSION; SIGNAL TRANSDUCTION; SOCIAL INTERACTION; SYNAPTIC TRANSMISSION;

EID: 84255190041     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.110011     Document Type: Review

References (126)

1. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002; 71: 533-54.
2. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001;52:503-17.
3. Seeman P, Weinshenker D, Quirion R, et al. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci U S A 2005;102:3513-8.
4. Snyder SH. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry 1976;133:197-202.
5. Torres GE, Gainetdinov RR, Caron MG. Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 2003;4:13-25.
6. Nagatsu T, Levitt M, Udenfriend S. Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J Biol Chem 1964;239:2910-7.
7. Zhang X, Beaulieu JM, Sotnikova TD, et al. Tryptophan hydroxylase- 2 controls brain serotonin synthesis. Science 2004;305:217.
8. Walther DJ, Peter JU, Bashammakh S, et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003;299:76.
9. Zhang X, Beaulieu JM, Gainetdinov RR, et al. Functional polymorphisms of the brain serotonin synthesizing enzyme tryptophan hydroxylase-2. Cell Mol Life Sci 2006;63:6-11.
10. Gainetdinov RR, Caron MG. Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol 2003;43:261-84.
11. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011;63:182-217.
12. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004;3:353-9.
13. Parsons MJ, Mata I, Beperet M, et al. A dopamine D2 receptor gene-related polymorphism is associated with schizophrenia in a Spanish population isolate. Psychiatr Genet 2007;17:159-63.
14. Bertram L. Genetic research in schizophrenia: new tools and future perspectives. Schizophr Bull 2008;34:806-12.
15. Rondou P, Haegeman G, Van Craenenbroeck K. The dopamine D4 receptor: biochemical and signalling properties. Cell Mol Life Sci 2010;67:1971-86.
16. Coghill D, Banaschewski T. The genetics of attention-deficit/ hyperactivity disorder. Expert Rev Neurother 2009;9:1547-65.
17. Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet 2009;126:51-90.
18. Le Foll B, Gallo A, Le Strat Y, et al. Genetics of dopamine receptors and drug addiction: a comprehensive review. Behav Pharmacol 2009; 20:1-17.
19. Wong AH, Buckle CE, Van Tol HH. Polymorphisms in dopamine receptors: What do they tell us? Eur J Pharmacol 2000;410:183-203.
20. Millar JK, Thomson PA, Wray NR, et al. Response to Amar J. Klar: The chromosome 1;11 translocation provides the best evidence supporting genetic etiology for schizophrenia and bipolar affective disorders. Genetics 2003;163:833-5, author reply 837-8.
21. Hall D, Gogos JA, Karayiorgou M. The contribution of three strong candidate schizophrenia susceptibility genes in demographically distinct populations. Genes Brain Behav 2004;3:240-8.
22. Beaulieu JM, Gainetdinov RR, Caron MG. Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 2009; 49: 327-47.
23. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980; 107: 519-27.
24. Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996; 15: 6541-51.
25. Cross DA, Alessi DR, Cohen P, et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378:785-9.
26. Woodgett JR. Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders. Curr Drug Targets Immune Endocr Metabol Disord 2003;3:281-90.
27. Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 2004;3:479-87.
28. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001; 2:769-76.
29. Borrelli E, Nestler EJ, Allis CD, et al. Decoding the epigenetic language of neuronal plasticity. Neuron 2008;60:961-74.
30. Scheid MP, Woodgett JR. PKB/AKT: functional insights from gen - etic models. Nat Rev Mol Cell Biol 2001;2:760-8.
31. Beaulieu JM, Sotnikova TD, Marion S, et al. An Akt/beta-Arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005;122:261-73.
32. Andjelkovi M, Jakubowicz T, Cron P, et al. Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc Natl Acad Sci U S A 1996;93:5699-704.
33. Ugi S, Imamura T, Maegawa H, et al. Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein Kinase B) activity in 3T3-L1 adipocytes. Mol Cell Biol 2004;24:8778-89.
34. Woodgett JR. Judging a protein by more than its name: GSK-3. Sci STKE 2001;2001:re12.
35. Stambolic V, Woodgett JR. Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J 1994;303:701-4.
36. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 1979;277:93-6.
37. Kebabian JW, Greengard P. Dopamine-sensitive adenyl cyclase: possible role in synaptic transmission. Science 1971;174:1346-9.
38. Enjalbert A, Bockaert J. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary. Mol Pharmacol 1983;23:576-84.
39. Missale C, Nash SR, Robinson SW, et al. Dopamine receptors: from structure to function. Physiol Rev 1998;78:189-225.
40. Perreault ML, Hasbi A, Alijaniaram M, et al. The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia. J Biol Chem 2010.
41. Rashid AJ, So CH, Kong MM, et al. D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci U S A 2007; 104: 654-9.
42. Zhang ZW, Burke MW, Calakos N, et al. Confocal analysis of cholinergic and dopaminergic inputs onto pyramidal cells in the prefrontal cortex of rodents. Front Neuroanat 2010;4:21.
43. Shuen JA, Chen M, Gloss B, et al. Drd1a-tdTomato BAC transgenic mice for simultaneous visualization of medium spiny neurons in the direct and indirect pathways of the basal ganglia. J Neurosci 2008; 28:2681-5.
44. Valjent E, Bertran-Gonzalez J, Herve D, et al. Looking BAC at striatal signaling: cell-specific analysis in new transgenic mice. Trends Neurosci 2009;32:538-47.
45. Bateup HS, Svenningsson P, Kuroiwa M, et al. Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci 2008;11:932-9.
46. Beaulieu JM, Sotnikova TD, Yao WD, et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A 2004; 101: 5099-104.
47. Beaulieu JM, Sotnikova TD, Gainetdinov RR, et al. Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice. J Biol Chem 2006;281:32072-80.
48. Chen PC, Lao CL, Chen JC. Dual alteration of limbic dopamine D1 receptor-mediated signalling and the Akt/GSK3 pathway in dopamine D3 receptor mutants during the development of methamphetamine sensitization. J Neurochem 2007;100:225-41.
49. Bychkov E, Ahmed MR, Dalby KN, et al. Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum. J Neurochem 2007;102:699-711.
50. Emamian ES, Hall D, Birnbaum MJ, et al. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 2004; 36:131-7.
51. Roh MS, Seo MS, Kim Y, et al. Haloperidol and clozapine differentially regulate signals upstream of glycogen synthase kinase 3 in the rat frontal cortex. Exp Mol Med 2007;39:353-60.
52. Beaulieu JM, Tirotta E, Sotnikova TD, et al. Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci 2007; 27: 881-5.
53. Shenoy SK, Lefkowitz RJ. Multifaceted roles of beta-Arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem J 2003;375:503-15.
54. Gainetdinov RR, Premont RT, Bohn LM, et al. Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 2004;27:107-44.
55. Lohse MJ, Benovic JL, Codina J, et al. Beta-Arrestin: a protein that regulates beta-adrenergic receptor function. Science 1990;248:1547-50.
56. Ferguson SS, Downey WE III, Colapietro AM, et al. Role of beta- Arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 1996;271:363-6.
57. Laporte SA, Miller WE, Kim KM, et al. Beta-Arrestin/AP-2 interaction in G protein-coupled receptor internalization: identification of a beta-Arrestin binging site in beta 2-adaptin. J Biol Chem 2002; 277: 9247-54.
58. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta- Arrestins. Science 2005;308:512-7.
59. Luttrell LM, Ferguson SS, Daaka Y, et al. Beta-Arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 1999;283:655-61.
60. Luttrell LM, Roudabush FL, Choy EW, et al. Activation and targeting of extracellular signal-regulated kinases by beta-Arrestin scaffolds. Proc Natl Acad Sci U S A 2001;98:2449-54.
61. Bohn LM, Lefkowitz RJ, Gainetdinov RR, et al. Enhanced morphine analgesia in mice lacking beta-Arrestin 2. Science 1999; 286: 2495-8.
62. Gainetdinov RR, Wetsel WC, Jones SR, et al. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 1999;283:397-401.
63. Beaulieu JM, Marion S, Rodriguiz RM, et al. A beta-Arrestin 2 signaling complex mediates lithium action on behavior. Cell 2008; 132: 125-36.
64. Bohn LM, Gainetdinov RR, Sotnikova TD, et al. Enhanced rewarding properties of morphine, but not cocaine, in beta(Arrestin)-2 knock-out mice. J Neurosci 2003;23:10265-73.
65. Zhou QY, Palmiter RD. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 1995;83:1197-209.
66. Sotnikova TD, Beaulieu JM, Barak LS, et al. Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol 2005;3:e271.
67. Gould TD, Einat H, Bhat R, et al. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 2004;7:387-90.
68. Kalinichev M, Dawson LA. Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania. Int J Neuropsychopharmacol 2011 Jan 6:1-17. [Epub ahead of print].
69. Hoeflich KP, Luo J, Rubie EA, et al. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000;406:86-90.
70. Polter A, Beurel E, Yang S, et al. Deficiency in the inhibitory serine- phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology 2010;35: 1761-74.
71. Prickaerts J, Moechars D, Cryns K, et al. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J Neurosci 2006;26:9022-9.
72. Powell SB, Geyer MA. Overview of animal models of schizophrenia. Curr Protoc Neurosci 2007;Chapter 9:Unit 9.24.
73. Carlsson A. Perspectives on the discovery of central monoaminergic neurotransmission. Annu Rev Neurosci 1987;10:19-40.
74. Yuan Q, Lin F, Zheng X, et al. Serotonin modulates circadian entrainment in Drosophila. Neuron 2005;47:115-27.
75. Li X, Rosborough KM, Friedman AB, et al. Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int J Neuropsychopharmacol 2007;10:7-19.
76. Li X, Zhu W, Roh MS, et al. In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 2004;29:1426-31.
77. Beaulieu JM. Not only lithium: regulation of glycogen synthase kinase-3 by antipsychotics and serotonergic drugs. Int J Neuropsychopharmacol 2007;10:3-6.
78. Zhang X, Gainetdinov RR, Beaulieu JM, et al. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 2005;45:11-6.
79. Beaulieu JM, Zhang X, Rodriguiz RM, et al. Role of GSK3beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci U S A 2008;105:1333-8.
80. Polter A, Yang S, Zmijewska AA, et al. Forkhead box, class O transcription factors in brain: regulation and behavioral manifestation. Biol Psychiatry 2009;65:150-9.
81. Jacinto E, Facchinetti V, Liu D, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006;127:125-37.
82. O'Brien WT, Harper AD, Jove F, et al. Glycogen synthase kinase- 3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 2004;24:6791-8.
83. Beaulieu JM, Zhang X, Rodriguiz RM, et al. Reply to Belmaker et al: GSK3β haploinsufficiency results in lithium-like effects in the forced swim test. Proc Natl Acad Sci U S A 2008;105:E24.
84. Ackermann TF, Kempe DS, Lang F, et al. Hyperactivity and enhanced curiosity of mice expressing PKB/SGK-resistant glycogen synthase kinase-3 (GSK-3). Cell Physiol Biochem 2010;25:775-86.
85. Beaulieu JM, Gainetdinov RR, Caron MG. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 2007; 28: 166-72.
86. Alimohamad H, Rajakumar N, Seah YH, et al. Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol Psychiatry 2005;57:533-42.
87. Masri B, Salahpour A, Didriksen M, et al. Antagonism of dopamine D2 receptor/beta-Arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci U S A 2008; 105:13656-61.
88. Sutton LP, Honardoust D, Mouyal J, et al. Activation of the canon - ical Wnt pathway by the antipsychotics haloperidol and clozapine involves dishevelled-3. J Neurochem 2007;102:153-69.
89. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 1996;93:8455-9.
90. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996;6:1664-8.
91. Beaulieu JM, Caron MG. Looking at lithium: molecular moods and complex behaviour. Mol Interv 2008;8:230-41.
92. De Sarno P, Li X, Jope RS. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 2002;43:1158-64.
93. Birch NJ. Lithium and magnesium-dependent enzymes [letter]. Lancet 1974;2:965-6.
94. Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 2001; 280:720-5.
95. Lai WS, Xu B, Westphal KG, et al. Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc Natl Acad Sci U S A 2006;103:16906-11.
96. Freyberg Z, Ferrando SJ, Javitch JA. Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry 2010;167:388-96.
97. Karege F, Perroud N, Schurhoff F, et al. Association of AKT1 gene variants and protein expression in both schizophrenia and bipolar disorder. Genes Brain Behav 2010;9:503-11.
98. Magno LA, Miranda DM, Neves FS, et al. Association between AKT1 but not AKTIP genetic variants and increased risk for sui - cidal behavior in bipolar patients. Genes Brain Behav 2010;9:411-8.
99. Benedetti F, Serretti A, Colombo C, et al. A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci Lett 2004;368:123-6.
100. Karege F, Perroud N, Burkhardt S, et al. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry 2007;61:240-5.
101. Ross CA, Margolis RL, Reading SA, et al. Neurobiology of schizophrenia. Neuron 2006;52:139-53.
102. Serretti A, Mandelli L. The genetics of bipolar disorder: genome 'hot regions,' genes, new potential candidates and future directions. Mol Psychiatry 2008;13:742-71.
103. Keri S, Seres I, Kelemen O, et al. The relationship among neuregulin 1-stimulated phosphorylation of AKT, psychosis proneness, and habituation of arousal in nonclinical individuals. Schizophr Bull 2011;37:141-7.
104. Kéri S, Beniczky S, Kelemen O. Suppression of the P50 evoked response and neuregulin 1-induced AKT phosphorylation in firstepisode schizophrenia. Am J Psychiatry 2010;167:444-50.
105. Sei Y, Li Z, Song J, et al. Epistatic and functional interactions of catechol-o-methyltransferase (COMT) and AKT1 on neuregulin1- ErbB signaling in cell models. PLoS ONE 2010;5:e10789.
106. Meyer-Lindenberg A, Nichols T, Callicott JH, et al. Impact of complex genetic variation in COMT on human brain function. Mol Psychiatry 2006;11:867-77, 797.
107. Sotnikova TD, Beaulieu JM, Espinoza S, et al. The dopamine metabolite 3-methoxytyramine is a neuromodulator. PLoS ONE 2010; 5:e13452.
108. Li YC, Xi D, Roman J, et al. Activation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated in - hibition of synaptic NMDA receptor function in the rat prefrontal cortex. J Neurosci 2009;29:15551-63.
109. Karam CS, Ballon JS, Bivens NM, et al. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol Sci 2010;31:381-90.
110. Du J, Wei Y, Liu L, et al. A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proc Natl Acad Sci U S A 2010;107:11573-8.
111. Mohn AR, Gainetdinov RR, Caron MG, et al. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999;98:427-36.
112. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010;329:959-64.
113. Chen L, Salinas GD, Li X. Regulation of serotonin 1B receptor by glycogen synthase kinase-3. Mol Pharmacol 2009;76:1150-61.
114. Chen L, Zhou W, Chen P, et al. Glycogen synthase kinase-3beta is a functional modulator of serotonin 1B receptors. Mol Pharmacol 2011; 79:974-86.
115. Li X, Jope RS. Is glycogen synthase kinase-3 a central modulator in mood regulation? Neuropsychopharmacology 2010;35:2143-54.
116. Dé Montigny C, Grunberg F, Mayer A, et al. Lithium induces rapid relief of depression in tricyclic antidepressant drug nonresponders. Br J Psychiatry 1981;138:252-6.
117. Valenstein M, McCarthy JF, Austin KL, et al. What happened to lithium? Antidepressant augmentation in clinical settings. Am J Psychiatry 2006;163:1219-25.
118. Costanzo M, Baryshnikova A, Bellay J, et al. The genetic landscape of a cell. Science 2010;327:425-31.
119. Beaulieu JM. Morphine-induced mu-opioid receptor internalization: a paradox solved in neurons. J Neurosci 2005;25:10061-3.
120. Chubb JE, Bradshaw NJ, Soares DC, et al. The Drosoph Inf ServC locus in psychiatric illness. Mol Psychiatry 2008;13:36-64.
121. Toyota T, Yamada K, Detera-Wadleigh SD, et al. Analysis of a cluster of polymorphisms in AKT1 gene in bipolar pedigrees: a family-based association study. Neurosci Lett 2003;339:5-8.
122. Bayer TA, Falkai P, Maier W. Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the "two hit hypothesis." J Psychiatr Res 1999;33:543-8.
123. Maynard TM, Sikich L, Lieberman JA, et al. Neural development, cell-cell signaling, and the "two-hit" hypothesis of schizophrenia. Schizophr Bull 2001;27:457-76.
124. Maziade M, Roy MA, Chagnon YC, et al. Shared and specific sus cept - ibility loci for schizophrenia and bipolar disorder: a dense genome scan in Eastern Quebec families. Mol Psychiatry 2005; 10: 486-99.
125. Knudson AG Jr. Mutation and cancer: statistical study of retino - blastoma. Proc Natl Acad Sci U S A 1971;68:820-3.
126. Devilee P, Cleton-Jansen AM, Cornelisse CJ. Ever since Knudson. Trends Genet 2001;17:569-73.